Abstract:Background & Aims: Non-alcoholic steatohepatitis (NASH) is associated with the dysregulation of lipid metabolism and hepatic inflammation. The causal mechanism underlying NASH is not fully elucidated. This study investigated the role of beta-Arrestin1 (ARRB1) in the progression of NASH. Methods: Liver tissue from patients with NASH and controls were obtained to evaluate ARRB1 expression. NASH models were established in Arrb1-knockout and wild-type mice fed either a high-fat diet (HFD) for 26 weeks or a methionine/choline-deficient (MCD) diet for 6 weeks. Results: ARRB1 expression was reduced in liver samples from patients with NASH. Reduced Arrb1 levels were also detected in murine NASH models. Arrb1 deficiency accelerated steatohepatitis development in HFD-/MCD-fed mice (accompanied by the upregulation of lipogenic genes and downregulation of beta-oxidative genes). Intriguingly, ARRB1 was found to interact with growth differentiation factor 15 (GDF15) and facilitated the transportation of GDF15 precursor (pro-GDF15) to the Golgi apparatus for cleavage and maturation. Treatment with recombinant GDF15 ablated the lipid accumulation in the presence of Arrb1 deletion both in vitro and in vivo. Re-expression of Arrb1 in the NASH models ameliorated the liver disease, and this effect was greater in the presence of pro-GDF15 overexpression. By contrast, the effect of pro-GDF15 overexpression alone was impaired in Arrb1-deficient mice. In addition, the severity of liver disease in patients with NASH was negatively correlated with ARRB1 expression. Conclusion: ARRB1 acts as a vital regulator in the development of NASH by facilitating the translocation of GDF15 to the Golgi apparatus and its subsequent maturation. Thus, ARRB1 is a potential therapeutic target for the treatment of NASH. Lay summary: Non-alcoholic steatohepatitis (NASH) is associated with the progressive dysfunction of lipid metabolism and a consequent inflammatory response. Decreased ARRB1 is observed in patients with NASH and murine NASH models. Re-expression of Arrb1 in the murine NASH model ameliorated liver disease, an effect which was more pronounced in the presence of pro-GDF15 overexpression, highlighting a promising strategy for NASH therapy. (c) 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Spin‐Label EPR on α‐Synuclein Reveals Differences in the Membrane Binding Affinity of the Two Antiparallel Helices

Tentative identification of beta-adrenoreceptor subunts.

MicroRNA-146b Regulates Hepatic Stellate Cell Activation Via Targeting of KLF4.

Biglycan promotes hepatic fibrosis through activating heat shock protein 47

The MSP‐RON Pathway Regulates Liver Fibrosis Through Transforming Growth Factor Beta‐dependent Epithelial–mesenchymal Transition

HSC-derived exosomal miR-199a-5p promotes HSC activation and hepatocyte EMT via targeting SIRT1 in hepatic fibrosis

ASIC1a promotes hepatic stellate cell activation through the exosomal miR-301a-3p/BTG1 pathway

The Upregulation of Leucine-Rich Repeat Containing 1 Expression Activates Hepatic Stellate Cells and Promotes Liver Fibrosis by Stabilizing Phosphorylated Smad2/3

MFAP2 promotes HSCs activation through FBN1/TGF‐β/Smad3 pathway

Fibroblast‐specific adipocyte enhancer binding protein 1 is a potential pathological trigger and prognostic marker for liver fibrosis independent of etiology

Aflatoxin B1-exposed hepatocyte-derived extracellular vesicles: Initiating hepatic stellate cell-mediated liver fibrosis through a p53-Parkin-dependent mitophagy pathway

Activated hepatic stellate cell-derived Bmp-1 induces liver fibrosis via mediating hepatocyte epithelial-mesenchymal transition

Autophagy affects hepatic fibrosis progression by regulating macrophage polarization and exosome secretion

ARRB1 Inhibits Non-Alcoholic Steatohepatitis Progression by Promoting GDF15 Maturation.

Exosomal miR-192-5p secreted by bone marrow mesenchymal stem cells inhibits hepatic stellate cell activation and targets PPP2R3A

Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression

The m6A reader IGF2BP1 contributes to the activation of hepatic stellate cells through facilitating TUBB4B mRNA stabilization

ATG16L1 Depletion-Mediated Activation of the TRAF1 Signaling in Macrophages Aggravates Liver Fibrosis

Interactions between Marek's disease herpesvirus and avian leucosis virus in tissue culture.

Parathyroid Hormone Receptor-1 Signaling Aggravates Hepatic Fibrosis Through Upregulating Camp Response Element-Binding Protein-Like 2.

miR221 regulates TGF-β1-induced HSC activation through inhibiting autophagy by directly targeting LAMP2